Table 2.
The characteristics of the 41 patients who underwent the examinations at 4 months
| Age, yrs.; mean (SD): | |
|---|---|
| Total | 63.0 (11.4) |
| < 65 | 21 (51) |
| ≥ 65 | 20 (49) |
| Gender: | |
| Male | 19 (46) |
| Female | 22 (54) |
| Primary cancer: | |
| Lung, non-small-cell | 24 (59) |
| Breast | 6 (15) |
| Lung, small-cell | 3 (7) |
| Others | 8 (19) |
| KPS: | |
| 100–90 | 15 (37) |
| 80 | 14 (34) |
| 70 | 7 (17) |
| 60 | 5 (12) |
| No. of brain metastases: | |
| Solitary | 10 (24) |
| Oligo (2–4) | 12 (29) |
| Multiple (5 = <) | 14 (34) |
| Meningeal carcinomatosis | 5 (12) |
| GPA: | |
| 4.0–3.0 | 4 (10) |
| 2.5–2.0 | 13 (32) |
| 1.5–1.0 | 18 (44) |
| 0.5–0.0 | 6 (14) |
| WBRT schedule: | |
| 35 Gy/14 fr | 36 (88) |
| 30 Gy/10 fr | 1 (2) |
| Others | 4 (10) |
| Treatment: | |
| WBRT only | 20 (49) |
| WBRT + SRS | 7 (17) |
| WBRT + Surgery (+/−SRS) | 14 (34) |
| Systemic therapies prior WBRT | |
| No | 16 (39) |
| Yes | 25 (61) |
| Cytotoxic chemotherapy | 22 (54) |
| Molecular targeted therapy | 11 (27) |
| Hormonal therapy | 4 (10) |
| Immunotherapy | 1 (2) |
| Systemic therapies after WBRT | |
| No | 6 (15) |
| Yes | 35 (85) |
| Cytotoxic chemotherapy | 19 (46) |
| Molecular targeted therapy | 19 (46) |
| Hormonal therapy | 2 (5) |
| Immunotherapy | 3 (7) |
| Intracranial control at 4 mos. | |
| PD | 13 (32) |
| Non-PD | 26 (63) |
| Unknown | 2 (5) |
Data are n (%) unless otherwise noted. KPS Karnofsky Performance Status, GPA Graded Prognosis Assessment, WBRT whole-brain radiotherapy, SRS stereotactic radiosurgery, BL baseline, PD progressive disease